Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
1-15 of 4028 results
Akashi gets FDA nod to restart clinical development of DMD drug HT-100
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
Contract Research & Services > Clinical Trials > News
Novartis’ serelaxin fails to meet primary endpoint in heart failure study
By PBR Staff Writer
Novartis' RLX030 (serelaxin) has failed to meet its primary endpoint in a phase III acute heart failure (AHF) study.
Contract Research & Services > Clinical Trials > News
Lilly’s abemaciclib meets primary endpoint in phase 3 breast cancer trial
By PBR Staff Writer
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Nektar’s NKTR-181 shown to reduce chronic pain in phase 3 trial
Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain.
Contract Research & Services > Clinical Trials > News
Novartis’ heart failure drug Entresto improves glycemic control in Phase III study
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.
Contract Research & Services > Clinical Trials > News
Amgen's Repatha lowers heart attack, stroke risk in phase 3 study
By PBR Staff Writer
A phase 3 study has demonstrated that Amgen’s cholesterol drug Repatha reduces low-density lipoprotein cholesterol (LDL-C) levels and risk of cardiovascular events.
Contract Research & Services > Clinical Trials > News
Catalyst Pharmaceuticals’ neuromuscular drug succeeds in seven-patient trial
By PBR Staff Writer
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza shows significant survival benefit in ovarian cancer study
By PBR Staff Writer
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo.
Contract Research & Services > Clinical Trials > News
Indivior plans to file NDA for schizophrenia drug in Q4 2017
Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia.
Contract Research & Services > Clinical Trials > News
Synairgen eyes lung fibrosis trial after positive data from LOXL2 inhibitor program
By PBR Staff Writer
Synairgen is on track to begin the initial clinical trial of a new lung fibrosis treatment later this year after pre-clinical work showed more evidence of improved breathing.
Contract Research & Services > Clinical Trials > News
BerGenBio signs deal with Merck to test lung and breast cancer combo
BerGenBio has signed a collaborative agreement with Merck focused the clinical study of BGB324 with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Contract Research & Services > Clinical Trials > News
Mereo BioPharma committee recommends continuation of BGS-649 study
Mereo BioPharma said that an independent data monitoring committee has recommended to continue all three different dose arms of the Phase 2b BGS-649 study after a prospectively defined interim analysis of safety and efficacy.
Contract Research & Services > Clinical Trials > News
TG Therapeutics’ cancer drug meets primary end point in phase 3 trial
By PBR Staff Writer
TG Therapeutics’ cancer drug, TG-1101 (ublituximab), in combination with AbbVie’s Imbruvica (ibrutinib), has met its primary end point in a phase 3 study in chronic lymphocytic leukemia (CLL) patients.
Contract Research & Services > Clinical Trials > News
FDA asks Scynexis to hold initiation of new clinical studies using IV formulation of SCY-078
Scynexis has been asked by the US Food and Drug Administration (FDA) to put a hold on the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until it finishes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078.
Contract Research & Services > Clinical Trials > News
Chi-Med’s colorectal cancer drug shows positive results in phase 3 trial
Hutchison China MediTech has unveiled top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer (“CRC”) in China, who failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan
Contract Research & Services > Clinical Trials > News
1-15 of 4028 results